WATCHMAN device for LAA: safety, efficacy confirmed in patients not using OACs

  • Boersma LV & al.
  • Circ Arrhythm Electrophysiol
  • 1 Apr 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Left atrial appendage (LAA) occlusion with WATCHMAN (Boston Scientific) leads to lower mortality and thromboembolism rates in patients for whom oral anticoagulation (OAC) is contraindicated.
  • Editorial finds results encouraging, notes that ASAP-TOO and STROKE-CLOSE will investigate LAA closure in this population.

Why this matters

  • Recent meta-analysis of PROTECT-AF and PREVAIL found WATCHMAN noninferior to vitamin K antagonists (VKA) for stroke prevention, with lower nonprocedural bleeding and mortality. 
  • Patients with OAC contraindication were not included in those trials.

Study design

  • Prospective multinational nonrandomized 2-year real-world EWOLUTION cohort study (n=1020).
  • Participants had nonvalvular Afib and were at high stroke risk; 72% ineligible for OAC.
  • Outcomes: mortality, bleeding, stroke/transient ischemic attack (TIA)/systemic embolism (SE).
  • Funding: Boston Scientific Corporation.

Key results

  • Dual antiplatelet therapy and OAC discontinued in 85%.
  • Deaths: 161 (16.4%; 95% CI, 13.8%-19.3%), mostly noncardiovascular.
  • Nonprocedural major bleeding: 
    • 46% relative risk reduction (RRR) vs expected rates with VKA.
    • Large RRR in higher-risk subgroups.
  • Ischemic stroke/TIA/SE: 
    • 80% RRR vs predicted by CHA2DS2-VASc.
    • Large RRR in higher-risk subgroups.
  • Device-related thrombus: 34 of 835 (4.1%) receiving routine LAA imaging; none had subsequent stroke/TIA/SE.

Limitations

  • Nonrandomized; no controls.
  • OAC contraindications unclear.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit